Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares S&P GSCI Commodity-Indexed Trust ETF vs Tango Therapeutics Inc. — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $36.59 (market cap $1.04B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 3.6× iShares S&P GSCI Commodity-Indexed Trust ETF's market cap, and iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares S&P GSCI Commodity-Indexed Trust ETF for 40 Days and Tango Therapeutics Inc. for 0 Days on average.
| GSG | TNGX | |
|---|---|---|
Market Cap | $1.04B | $3.75B |
Volume | 1,727,795 | 9,619,106 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.15 | $32.90 |
52-Week Low | $22.48 | $7.50 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSG trades at $36.77, up 0.96% with strong bullish technical signals from moving averages. The ETF shows volatile fundamentals with 2024 revenue of $51.25M and net income of $69.99M, though historical trends reveal significant profit margin swings from -126.61% in 2023 to 136.56% in 2024. Recent media coverage highlights commodity-focused positioning with energy exposure driving performance.
Outlook remains cautiously optimistic given bullish technical indicators and commodity market strength, but investors face volatility risks from energy sector exposure and geopolitical factors. The ETF's performance is heavily tied to broader commodity cycles, requiring careful monitoring of energy markets and global economic conditions.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
